Novo Nordisk's Wegovy Exceeds 130,000 Weekly Prescriptions in North America

Thursday, 2 May 2024, 07:53

Novo Nordisk's injectable drug Wegovy, aimed at weight loss, has now surpassed 130,000 weekly prescriptions in North America. The company's decision to increase supplies due to overwhelming demand has positively impacted its financial outlook.
https://store.livarava.com/6edfdc8d-0859-11ef-a6c0-63e1980711b2.jpg
Novo Nordisk's Wegovy Exceeds 130,000 Weekly Prescriptions in North America

Novo Nordisk's Wegovy Weight-Loss Drug Achieves Milestone

Novo Nordisk has seen significant success with its injectable weight-loss drug, Wegovy, which now boasts over 130,000 weekly prescriptions in North America alone. The company's proactive response to escalating demand by ramping up supplies has bolstered its financial performance.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe